Skip to main content
. Author manuscript; available in PMC: 2021 May 10.
Published in final edited form as: J Control Release. 2020 Jan 29;321:272–284. doi: 10.1016/j.jconrel.2020.01.051

FIG. 8.

FIG. 8.

Evaluation of systemic cytokine expression changes upon UTMD-mediated miRNA delivery. Mice were engrafted with Hepa1–6 tumors on both hind limbs. Only one tumor was treated (T) while the other was used as a contralateral control (CL). Cytokine expressions were assessed in tumor-associated lymph nodes prior to treatment (control) and 0.5, 6, and 24 h after treatment with UTMD-mediated delivery of miR-122-/anti-miR-21-loaded NPs. For statistical analysis, all treated and contralateral samples were compared to the untreated control.